GDME1031FPR Coronary Stents – Current and …Coronary Stents – Current and Future Players 2 ©...

REFERENCE CODE GDME1031FPR | PUBLICATION DATE NOVEMBER 2014

CORONARY STENTS – CURRENT AND FUTURE PLAYERS

Coronary Stents – Current and Future Players 2 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.

Table of Contents


1 Table of Contents

1 Table of Contents ....................................................................................................................... 2

1.1 List of Tables ...................................................................................................................... 6

1.2 List of Figures ................................................................................................................... 12

2 Introduction ............................................................................................................................... 13

2.1 Catalyst ............................................................................................................................. 14

2.2 Related Reports ................................................................................................................ 15

3 Competitive Assessment .......................................................................................................... 16

3.1 Overview ........................................................................................................................... 16

3.2 Trends in Coronary Stent Technology Development ......................................................... 17

3.2.1 Development of Bare Metal Stents ................................................................................ 17

3.2.2 Development of Drug-Eluting Stents ............................................................................. 19

3.2.3 Development of Bioabsorbable Stents........................................................................... 22

3.2.4 Development of Covered Stents .................................................................................... 23

3.2.5 Coronary Stent Technology SWOT Analysis ................................................................. 24

4 Pipeline Products ...................................................................................................................... 25

4.1 Overview ........................................................................................................................... 25

4.2 Pipeline by Stage of Development .................................................................................... 25

4.3 Pipeline Product Profiles ................................................................................................... 28

4.3.1 Bioabsorbable Stents .................................................................................................... 28

4.3.2 Other Types of Vascular Stents ..................................................................................... 39

5 Current and Future Players ....................................................................................................... 45


Table of Contents


5.1 Overview ........................................................................................................................... 45

5.2 Trends in Corporate Strategy ............................................................................................ 45

5.3 Company Profiles .............................................................................................................. 48

5.3.1 Abbott Vascular ............................................................................................................. 48

5.3.2 Boston Scientific Corporation ........................................................................................ 54

5.3.3 Medtronic ...................................................................................................................... 60

5.3.4 Alvimedica ..................................................................................................................... 66

5.3.5 Amaranth Medical ......................................................................................................... 70

5.3.6 amg International .......................................................................................................... 73

5.3.7 Arterial Remodeling Technologies ................................................................................. 77

5.3.8 B. Braun ........................................................................................................................ 80

5.3.9 Balton ............................................................................................................................ 83

5.3.10 Biosensors International ................................................................................................ 88

5.3.11 Biotronik ........................................................................................................................ 92

5.3.12 Blue Medical.................................................................................................................. 97

5.3.13 Cardionovum ............................................................................................................... 101

5.3.14 C.R. Bard .................................................................................................................... 105

5.3.15 Elixir Medical Corporation............................................................................................ 109

5.3.16 eucatech AG ............................................................................................................... 114

5.3.17 Hexacath ..................................................................................................................... 118

5.3.18 IRAMED ...................................................................................................................... 121

5.3.19 JW Medical Systems ................................................................................................... 124

5.3.20 Kyoto Medical Planning ............................................................................................... 127


Table of Contents


5.3.21 Lepu Medical Technology............................................................................................ 130

5.3.22 MicroPort Scientific Corporation .................................................................................. 134

5.3.23 Minvasys ..................................................................................................................... 138

5.3.24 MIV Therapeutics ........................................................................................................ 142

5.3.25 Opto Circuits ............................................................................................................... 146

5.3.26 OrbusNeich Medical .................................................................................................... 150

5.3.27 Relisys Medical Devices .............................................................................................. 154

5.3.28 REVA Medical ............................................................................................................. 158

5.3.29 Sahajanand Medical Technologies .............................................................................. 161

5.3.30 STENTYS ................................................................................................................... 165

5.3.31 Terumo Corporation .................................................................................................... 169

5.3.32 Translumina ................................................................................................................ 173

5.3.33 Vascular Concepts ...................................................................................................... 176

5.3.34 Other Companies ........................................................................................................ 180

6 Appendix................................................................................................................................. 192

6.1 Bibliography .................................................................................................................... 192

6.2 Abbreviations .................................................................................................................. 216

6.3 Report Methodology ........................................................................................................ 223

6.3.1 Overview ..................................................................................................................... 223

6.3.2 Coverage .................................................................................................................... 223

6.3.3 Secondary Research ................................................................................................... 223

6.4 Physicians and Specialists Included in This Study .......................................................... 225

6.4.1 Praveen Chandra, MD, DM, FESC, FSCAI, FAPSCI ................................................... 225


Table of Contents


6.4.2 Bernado Cortese, MD, FESC ...................................................................................... 225

6.4.3 Ricardo A. Costa, MD .................................................................................................. 225

6.4.4 Thomas Cuisset, MD, PhD, FESC ............................................................................... 225

6.4.5 Nobuyuki Komiyama, MD, PhD, FACC, FJCC ............................................................. 225

6.4.6 Roger J. Laham, MD ................................................................................................... 225

6.4.7 Mark W. Mewissen, MD .............................................................................................. 225

6.4.8 Gary S. Mintz, MD ....................................................................................................... 225

6.4.9 Tudor C. Poerner, MD ................................................................................................. 226

6.4.10 David Ramsdale, MD, PhD.......................................................................................... 226

6.4.11 Gregory A. Sgueglia, MD, PhD .................................................................................... 226

6.4.12 Madhukar Shahi, MD ................................................................................................... 226

6.4.13 Takehiro Yamashita, MD, PhD, FACC......................................................................... 226

6.5 Primary Research ........................................................................................................... 227

6.5.1 Primary Research – Key Opinion Leader Interviews.................................................... 227

6.5.2 Primary Research Interviews– Physician and Industry Participants ............................. 227

6.5.3 Physican Survey ......................................................................................................... 228

6.5.4 Expert Panel Validation ............................................................................................... 229

6.6 Forecasting Methodology ................................................................................................ 230

6.7 About the Authors ........................................................................................................... 232

6.7.1 Analysts ...................................................................................................................... 232

6.7.2 Global Head of Healthcare .......................................................................................... 233

6.8 About MediPoint .............................................................................................................. 234

6.9 About GlobalData ............................................................................................................ 234


Table of Contents


6.10 Disclaimer ....................................................................................................................... 234

1.1 List of Tables

Table 1: Coronary Stent Technology SWOT Analysis, 2014 ........................................................................... 24

Table 2: Global Coronary Stent Pipeline Products, 2014 ................................................................................ 27

Table 3: ART18Z SWOT Analysis, 2014 ........................................................................................................ 29

Table 4: DREAMS SWOT Analysis, 2014 ...................................................................................................... 30

Table 5: Fantom SWOT Analysis, 2014 ......................................................................................................... 31

Table 6: Fortitude SWOT Analysis, 2014 ....................................................................................................... 32

Table 7: Ideal BioStent SWOT Analysis, 2014 ............................................................................................... 33

Table 8: Igaki-Tamai Stent SWOT Analysis, 2014 .......................................................................................... 35

Table 9: ON-AVS SWOT Analysis, 2014 ........................................................................................................ 36

Table 10: Other Companies Developing BAS, 2014 ....................................................................................... 39

Table 11: FOCUS np Eluting Stent SWOT Analysis, 2014.............................................................................. 40

Table 12: STENTYS Sirolimus-Eluting Stent SWOT Analysis, 2014 ............................................................... 41

Table 13: Svelte Drug-Eluting Stent SWOT Analysis, 2014 ............................................................................ 43

Table 14: Abbott Vascular Company Profile ................................................................................................... 48

Table 15: Abbott Vascular Coronary Stent Marketed Products ....................................................................... 50

Table 16: Abbott Vascular Coronary Stent Product Portfolio SWOT Analysis, 2014 ........................................ 53

Table 17: Abbott Vascular SWOT Analysis, 2014 ........................................................................................... 54

Table 18: Boston Scientific Corporation Company Profile ............................................................................... 55

Table 19: Boston Scientific Coronary Stent Marketed Products ...................................................................... 57

Table 20: Boston Scientific Coronary Stent Product Portfolio SWOT Analysis, 2014....................................... 59

Table 21: Boston Scientific Corporation SWOT Analysis, 2014 ...................................................................... 60


Table of Contents


Table 22: Medtronic Company Profile ............................................................................................................ 61

Table 23: Medtronic Coronary Stent Marketed Products ................................................................................ 63

Table 24: Medtronic Coronary Stent Product Portfolio SWOT Analysis, 2014 ................................................. 65

Table 25: Medtronic SWOT Analysis, 2014 .................................................................................................... 66

Table 26: Alvimedica Company Profile ........................................................................................................... 67

Table 27: Alvimedica Coronary Stent Marketed Products ............................................................................... 68

Table 28: Alvimedica Coronary Stent Product Portfolio SWOT Analysis, 2014 ............................................... 69

Table 29: Alvimedica SWOT Analysis, 2014 .................................................................................................. 70

Table 30: Amaranth Medical Company Profile ............................................................................................... 71

Table 31: Amaranth Medical Coronary Stent Pipeline Product........................................................................ 71

Table 32: Amaranth Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 .................................... 72

Table 33: Amaranth Medical SWOT Analysis, 2014 ....................................................................................... 72

Table 34: amg International Company Profile ................................................................................................. 73

Table 35: amg International Coronary Stent Marketed Products ..................................................................... 75

Table 36: amg International Coronary Stent Product Portfolio SWOT Analysis, 2014 ..................................... 76

Table 37: amg International SWOT Analysis, 2014 ........................................................................................ 77

Table 38: Arterial Remodeling Technologies Company Profile ....................................................................... 78

Table 39: Arterial Remodeling Technologies Coronary Stent Pipeline Product ............................................... 78

Table 40: Arterial Remodeling Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014 ............ 79

Table 41: Arterial Remodeling Technologies SWOT Analysis, 2014 ............................................................... 79

Table 42: B. Braun Company Profile .............................................................................................................. 80

Table 43: B. Braun Coronary Stent Marketed Products .................................................................................. 81

Table 44: B. Braun Coronary Stent Product Portfolio SWOT Analysis, 2014 ................................................... 82

Table 45: B. Braun SWOT Analysis, 2014 ...................................................................................................... 83


Table of Contents


Table 46: Balton Company Profile .................................................................................................................. 84

Table 47: Balton Coronary Stent Marketed Products ...................................................................................... 85

Table 48: BALTON Coronary Stent Product Portfolio SWOT Analysis, 2014 .................................................. 87

Table 49: Balton SWOT Analysis, 2014 ......................................................................................................... 87

Table 50: Biosensors International Company Profile ...................................................................................... 88

Table 51: Biosensors International Coronary Stent Marketed Products .......................................................... 90

Table 52: Biosensors International Coronary Stent Product Portfolio SWOT Analysis, 2014 ........................... 91

Table 53: Biosensors International SWOT Analysis, 2014 .............................................................................. 92

Table 54: Biotronik Company Profile .............................................................................................................. 93

Table 55: Biotronik Coronary Stent Marketed and Pipeline Products .............................................................. 94

Table 56: Biotronik Coronary Stent Product Portfolio SWOT Analysis, 2014 ................................................... 96

Table 57: Biotronik SWOT Analysis, 2014 ...................................................................................................... 97

Table 58: Blue Medical Company Profile ........................................................................................................ 98

Table 59: Blue Medical Coronary Stent Marketed Products ............................................................................ 99

Table 60: Blue Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 .......................................... 100

Table 61: Blue Medical SWOT Analysis, 2014 ............................................................................................. 101

Table 62: Cardionovum Company Profile ..................................................................................................... 102

Table 63: Cardionovum Coronary Stent Marketed and Pipeline Products ..................................................... 103

Table 64: Cardionovum Coronary Stent Product Portfolio SWOT Analysis, 2014 .......................................... 104

Table 65: Cardionovum SWOT Analysis, 2014............................................................................................. 105

Table 66: C.R. Bard Company Profile .......................................................................................................... 106

Table 67: ClearStream Technologies Coronary Stent Marketed Products..................................................... 107

Table 68: C.R. Bard Coronary Stent Product Portfolio SWOT Analysis, 2014 ............................................... 108

Table 69: C.R. Bard SWOT Analysis, 2014 .................................................................................................. 109


Table of Contents


Table 70: Elixir Medical Corporation Company Profile .................................................................................. 110

Table 71: Elixir Medical Corporation Coronary Stent Marketed Products ...................................................... 111

Table 72: Elixir Medical Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014 ....................... 113

Table 73: Elixir Medical Corporation SWOT Analysis, 2014 .......................................................................... 114

Table 74: eucatech Profile ........................................................................................................................... 115

Table 75: eucatech Coronary Stent Marketed Products ................................................................................ 116

Table 76: eucatech Coronary Stent Product Portfolio SWOT Analysis, 2014 ................................................ 117

Table 77: eucatech SWOT Analysis, 2014 ................................................................................................... 118

Table 78: Hexacath Company Profile ........................................................................................................... 119

Table 79: Hexacath Coronary Stent Marketed Products ............................................................................... 120

Table 80: Hexacath Coronary Stent Product Portfolio SWOT Analysis, 2014................................................ 120

Table 81: Hexacath SWOT Analysis, 2014................................................................................................... 121

Table 82: IRAMED Company Profile ............................................................................................................ 121

Table 83: IRAMED Coronary Stent Marketed Products ................................................................................ 122

Table 84: IRAMED Coronary Stent Product Portfolio SWOT Analysis, 2014 ................................................. 123

Table 85: IRAMED SWOT Analysis, 2014 .................................................................................................... 124

Table 86: JW Medical Systems Company Profile ......................................................................................... 125

Table 87: JW Medical Systems Coronary Stent Marketed Product ............................................................... 125

Table 88: JW Medical Systems’ Coronary Stent Product Portfolio SWOT Analysis, 2014 ............................. 126

Table 89: JW Medical Systems SWOT Analysis, 2014 ................................................................................. 127

Table 90: Kyoto Medical Planning Company Profile ..................................................................................... 128

Table 91: Kyoto Medical Planning Coronary Stent Pipeline Product ............................................................. 129

Table 92: Kyoto Medical Planning Coronary Stent Product Portfolio SWOT Analysis, 2014 .......................... 129

Table 93: Kyoto Medical Planning SWOT Analysis, 2014 ............................................................................. 130


Table of Contents


Table 94: Lepu Medical Technology Company Profile .................................................................................. 131

Table 95: Lepu Medical Technology Coronary Stent Marketed and Pipeline Products .................................. 132

Table 96: Lepu Medical Technology Coronary Stent Product Portfolio SWOT Analysis, 2014 ....................... 133

Table 97: Lepu Medical Technology SWOT Analysis, 2014.......................................................................... 134

Table 98: MicroPort Scientific Corporation Company Profile ......................................................................... 135

Table 99: MicroPort Scientific Corporation Coronary Stent Marketed Products ............................................. 136

Table 100: MicroPort Scientific Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014............ 137

Table 101: MicroPort Scientific Corporation SWOT Analysis, 2014 .............................................................. 138

Table 102: Minvasys Company Profile ......................................................................................................... 139

Table 103: Minvasys Coronary Stent Marketed and Pipeline Products ......................................................... 140

Table 104: Minvasys Coronary Stent Product Portfolio SWOT Analysis, 2014 .............................................. 141

Table 105: Minvasys SWOT Analysis, 2014 ................................................................................................. 142

Table 106: MIV Therapeutics Company Profile ............................................................................................ 143

Table 107: MIV Therapeutics Coronary Stent Marketed Products ................................................................. 144

Table 108: MIV Therapeutics Coronary Stent Product Portfolio SWOT Analysis, 2014 ................................. 145

Table 109: MIV Therapeutics SWOT Analysis, 2014 .................................................................................... 146

Table 110: Opto Circuits Company Profile ................................................................................................... 147

Table 111: Opto Circuits Coronary Stent Marketed Products ........................................................................ 148

Table 112: Opto Circuits Coronary Stent Product Portfolio SWOT Analysis, 2014 ........................................ 149

Table 113: Opto Circuits SWOT Analysis, 2014 ........................................................................................... 150

Table 114: OrbusNeich Medical Company Profile ........................................................................................ 151

Table 115: OrbusNeich Medical Coronary Stent Marketed and Pipeline Products ........................................ 152

Table 116: OrbusNeich Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 ............................. 153

Table 117: OrbusNeich Medical SWOT Analysis, 2014 ................................................................................ 154


Table of Contents


Table 118: Relisys Medical Devices Company Profile .................................................................................. 155

Table 119: Relisys Medical Devices Coronary Stent Marketed Products ...................................................... 156

Table 120: Relisys Medical Devices Coronary Stent Product Portfolio SWOT Analysis, 2014 ....................... 157

Table 121: Relisys Medical Devices SWOT Analysis, 2014 .......................................................................... 158

Table 122: REVA Medical Company Profile ................................................................................................. 159

Table 123: REVA Medical Coronary Stent Pipeline Product ......................................................................... 159

Table 124: REVA Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 ...................................... 160

Table 125: REVA Medical SWOT Analysis, 2014 ......................................................................................... 161

Table 126: Sahajanand Medical Technologies Company Profile................................................................... 162

Table 127: Sahajanand Medical Technologies Coronary Stent Marketed and Pipeline Products ................... 163

Table 128: Sahajanand Medical Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014 ....... 164

Table 129: Sahajanand Medical Technologies SWOT Analysis, 2014 .......................................................... 165

Table 130: STENTYS Company Profile........................................................................................................ 166

Table 131: STENTYS Coronary Stent Marketed and Pipeline Products ........................................................ 167

Table 132: STENTYS Coronary Stent Product Portfolio SWOT Analysis, 2014 ............................................ 168

Table 133: STENTYS SWOT Analysis, 2014 ............................................................................................... 169

Table 134: Terumo Corporation Company Profile ........................................................................................ 170

Table 135: Terumo Corporation Coronary Stent Marketed and Pipeline Products ......................................... 171

Table 136: Terumo Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014 ............................. 172

Table 137: Terumo Corporation SWOT Analysis, 2014 ................................................................................ 172

Table 138: Translumina Company Profile .................................................................................................... 173

Table 139: Translumina Coronary Stent Marketed Products ......................................................................... 174

Table 140: Translumina Coronary Stent Product Portfolio SWOT Analysis, 2014 ......................................... 175

Table 141: Translumina SWOT Analysis, 2014 ............................................................................................ 175


Table of Contents


Table 142: Vascular Concepts Company Profile .......................................................................................... 176

Table 143: Vascular Concepts Coronary Stent Marketed Products ............................................................... 177

Table 144: Vascular Concepts Coronary Stent Product Portfolio SWOT Analysis, 2014 ............................... 178

Table 145: Vascular Concepts SWOT Analysis, 2014 .................................................................................. 179

Table 146: Other Companies in the Coronary Stent Market, North America, 2014 ........................................ 180

Table 147: Other Companies in the Coronary Stent Market, EU, 2014 ......................................................... 185

Table 148: Other Companies in the Coronary Stent Market, APAC, 2014..................................................... 188

Table 149: Other Companies in the Coronary Stent Market, South Africa and South America, 2014 ............. 191

Table 150: Primary Research Interviews Completed .................................................................................... 228

Table 151: Physicians Surveyed, By Country ............................................................................................... 229

1.2 List of Figures

Figure 1: Global Coronary Stents Market Value Share (%), 2013 and 2020 .................................................... 17

Figure 2: Global Coronary Stent Pipeline Products by Stage of Development, 2014 ....................................... 26


Introduction


2 Introduction

Coronary artery disease (CAD) is a global public health and socioeconomic problem that affects

millions of lives each year. Percutaneous coronary interventions (PCIs), such as stenting and

angioplasty, have been widely adopted worldwide to treat a range of CAD indications. The

coronary stent market is a dynamic and competitive one that is saturated with numerous players

trying to gain share by developing innovative technologies. Coronary stents, which include bare

metal, drug-eluting, covered, and bioabsorbable stents (BAS), can be used for a range of

indications in CAD, including de novo stenosis, acute myocardial infarction (AMI) (heart attack),

bifurcation lesions, SVD, saphenous vein grafts (SVGs), left main coronary artery disease

(LMCAD) and chronic total occlusions (CTOs).

Among the different types of stents, drug-eluting stents (DES) are considered to be the gold

standard of treatment and will continue to dominate the global coronary stents market in the future.

Since the development of the first generation of DES, manufacturers have focused on optimizing

and developing innovative low-profile platforms, stent coatings, drug-eluting components, and

materials. These innovations have improved the deliverability, performance, and safety profile of

stents, leading to better outcomes and reducing the risk of restenosis and complications such as

chronic inflammation and late stent thrombosis. Emerging stent technologies, such as DES with

biodegradable polymer/polymer-free coatings and BAS, are viable alternatives to and can address

the complications associated with the contemporary stents. BAS are a breakthrough technology

that can provide transient support to the vessel and completely degrade over time.

This report focuses on the global coronary stents market for treating CAD. The global coronary

stents market is determined for the 10 countries covered in the report, which are the US, France,

Germany, Italy, Spain, the UK, Japan, Brazil, China, and India. This report identifies the unmet

needs in the market for treating CAD that are associated with current stent technologies, provides

an understanding of physicians’ perceptions and decision-making process in using different types

of stents, and evaluates the adoption of the different types of coronary stents in the future. From

GlobalData’s analysis, it is evident that DES currently have and will continue to command the

largest share in the global coronary stents market. The widespread adoption of DES can be

attributed to improved outcomes, the availability of long-term clinical evidence, and the reduced

need for repeat intervention, thereby incurring cost savings for healthcare providers. In addition, the

current adoption of emerging stent technologies, such as the next generation of DES and BAS, is

Drug-eluting stents are considered to be the gold standard of treatment and will continue to dominate the global coronary stents market in the future.


Introduction


slow. BAS, such as the Absorb BVS and DESolve, have received only CE Mark approval and are

available only in selected markets. Large-scale, long-term cost-effectiveness studies need to be

conducted to demonstrate their clinical efficacy, so that these innovative technologies can be

integrated appropriately into the existing reimbursement systems.

2.1 Catalyst

Stent technology has revolutionized the field of interventional cardiology such that coronary

stenting has become the standard of care for patients with CAD. Modern developments in PCI

have led to a paradigm shift in the treatment of CAD towards stenting. Among the coronary stents,

DES dominate the coronary stents market worldwide, and physicians have extensive clinical

experience using these devices. Unlike bare metal stents (BMS) and covered stents (CS), DES

elute an antiproliferative agent, which can significantly reduce restenosis and target lesion

revascularization (TLR) rates.

Vascular stent technology has evolved over the years and is used in clinical practice for different

types of lesions/indications, such as de novo stenosis, bifurcation lesions, and small-vessel

disease (SVD). Although stent technologies such as DES have reduced the risk of restenosis and

the need for repeat revascularization, and also provide mechanical support to the vessel,

complications such as late and very late stent thrombosis, chronic inflammation, and dependency

on prolonged dual antiplatelet therapy reiterate the need for new treatment modalities. In addition,

the presence of polymer coatings on DES can lead to chronic inflammation and hypersensitivity

reactions, resulting in poor clinical outcomes and endangering patient safety. The next generation

of coronary stents is being developed with innovative stent structures, thinner struts, more effective

antiproliferative drugs, durable metal alloys, biodegradable polymer coatings, bioactive and

polymer-free coatings, and fully-absorbable stent platforms. BAS offer several benefits, including

eliminating the need for stent-in-stent procedures, thereby potentially reducing the need for

prolonged dual antiplatelet therapy, enhanced vessel healing, and improving the feasibility of future

interventions.

As more long-term clinical data demonstrating the superior therapeutic benefits of BAS and

reimbursement become available, the adoption of BAS by the medical community will increase

slowly in the future. As CAD is an enormous global public health and socioeconomic problem, and

the use of stents continues to increase, it is important to find effective treatment modalities that

ensure long-term quality results for patients. This report looks at the current coronary stents market

Modern developments in PCI have led to a paradigm shift in the treatment of CAD towards stenting.


Introduction


for CAD in various regions, and evaluates the adoption and opportunities for these technologies in

the 10 major markets (10MM).

2.2 Related Reports

GlobalData (2012). Bioabsorbable Stents – Global Market Analysis and Forecasts, December

2012, GDME0164MAR

GlobalData (2013). Drug Eluting Balloons – Global Market Analysis and Forecasts, September

2013, GDME0179MAR


Appendix


6.8 About MediPoint

MediPoint is the flagship product for GlobalData’s Medical team. Each MediPoint report is built

from the ground up by our team of healthcare analysts in the US and UK. Each report includes

input from experienced physicians and leading KOLs. Running throughout each report in the

series, the “What Physicians Think” quotes provide unique insight into how healthcare

professionals are reacting to events within the industry, and what their responses could mean for

industry strategists.

6.9 About GlobalData

GlobalData is a leading global provider of business intelligence in the healthcare industry.

GlobalData provides its clients with up-to-date information and analysis on the latest developments

in drug research, disease analysis, and clinical research and development. Our integrated business

intelligence solutions include a range of interactive online databases, analytical tools, reports, and

forecasts. Our analysis is supported by a 24/7 client support and analyst team.

GlobalData has offices in New York, San Francisco, Boston, London, India, Korea, Tokyo, Japan,

Singapore, and Australia.

6.10 Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any

form by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior

permission of the publisher, GlobalData.

GDME1031FPR Coronary Stents – Current and …Coronary Stents – Current and Future Players 2 ©...

Documents

Transcript of GDME1031FPR Coronary Stents – Current and …Coronary Stents – Current and Future Players 2 ©...